Reminder of the news expected (plus a couple bonus ones perhaps as a part of the Iceberg?)
In H1 CY 2023, shareholders can expect:
Clinical
o Updates on the Phase 2 relapsed/refractory (R/R) AML combination trial in Israel
o Updates on the Phase 1/2 EMD AML trial with first patient recruitment expected
o Updates on new Zantrene formulation manufacturing progress.
Preclinical
o Updates on both cell and animal studies supporting the cardioprotection program
o Updates on cell and animal studies exploring the optimal combination of Zantrene with the standard of care drugs doxorubicin and cyclophosphamide
o Updates on dose ranging studies of Zantrene and a kinase inhibitor in a rat model of clear cell renal cell carcinoma (kidney cancer)
o Updates on dose ranging and cardioprotection studies in mouse models of multiple myeloma and cardioprotection
o An update on a human derived mouse model of AML study, exploring the optimal combination of decitabine and Zantrene as a low toxicity treatment for AML
o Updates on studies exploring the potential utility of Zantrene as an anti-cancer agent across more than 100 cancer types.
General Comments / Chat, page-6538
-
-
- There are more pages in this discussion • 5,346 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.59 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M |
Open | High | Low | Value | Volume |
$1.61 | $1.62 | $1.55 | $189.9K | 121.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1316 | $1.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.59 | 34961 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1316 | 1.580 |
1 | 400 | 1.560 |
2 | 8157 | 1.550 |
1 | 6250 | 1.540 |
1 | 25000 | 1.530 |
Price($) | Vol. | No. |
---|---|---|
1.590 | 34961 | 1 |
1.595 | 3134 | 2 |
1.600 | 3000 | 1 |
1.650 | 17029 | 2 |
1.690 | 6570 | 3 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online